Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05587543 | Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma | recruiting | Early Phase 1 | 24 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05108428 | Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma | active not recruiting | Early Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05651828 | Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma | recruiting | Early Phase 1 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06435351 | Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy | recruiting | Early Phase 1 | 16 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07505069 | Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors | recruiting | Early Phase 1 | 10 | Nanolattix Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04040088 | An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors | active not recruiting | Early Phase 1 | 20 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07376642 | A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | recruiting | Early Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07071155 | Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia(M-HArbOr) | recruiting | Early Phase 1 | 18 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07498595 | TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC | not yet recruiting | Early Phase 1 | 50 | Tianjin Medical University General HospitalOTHER | 0 | Mar 27, 2026 | clinicaltrials |
| NCT06789081 | GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02) | active not recruiting | Early Phase 1 | 1 | AHS Cancer Control AlbertaOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07089940 | OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Early Phase 1 | 12 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07487597 | Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors | recruiting | Early Phase 1 | 24 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05702398 | Pilot Trial of Supplemental Vitamin A and Nicotinamide | recruiting | Early Phase 1 | 30 | Rhode Island HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04862260 | Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma | active not recruiting | Early Phase 1 | 3 | CHU de Quebec-Universite LavalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04655404 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 5 | Mar 18, 2026 | clinicaltrials |
| NCT07048249 | Single Arm Romiplostim to Prevent CIT | recruiting | Early Phase 1 | 26 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05291507 | Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System(BreastMRgFUS) | recruiting | Early Phase 1 | 34 | University of UtahOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07476027 | Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL | not yet recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT05294367 | Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma | recruiting | Early Phase 1 | 60 | Mayo ClinicOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07475182 | Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers | recruiting | Early Phase 1 | 10 | Hainan Cancer HospitalOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07470073 | A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults | recruiting | Early Phase 1 | 18 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06142396 | Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure | recruiting | Early Phase 1 | 30 | Augusta UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06890494 | Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia | recruiting | Early Phase 1 | 3 | Beijing GoBroad HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07164027 | Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial | recruiting | Early Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05076513 | Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma | active not recruiting | Early Phase 1 | 42 | Nader SanaiOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05182905 | AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients | active not recruiting | Early Phase 1 | 97 | Nader SanaiOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07458659 | Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma(CART-BCMA) | not yet recruiting | Early Phase 1 | 3 | Chulalongkorn UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07458919 | Therapy for Advanced NSCLC With EGFR 19delins Mutation | not yet recruiting | Early Phase 1 | 94 | Fuzhou General HospitalOTHER | 0 | Mar 9, 2026 | clinicaltrials |
| NCT02933736 | Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients | active not recruiting | Early Phase 1 | 48 | Nader SanaiOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07254091 | Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer | recruiting | Early Phase 1 | 10 | Northwell HealthOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03832569 | Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors | active not recruiting | Early Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07274813 | A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors | recruiting | Early Phase 1 | 254 | Shanghai Henlius BiotechINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07420036 | An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, in Patients With Malignant Tumors(SFB6-ZN01 PET) | not yet recruiting | Early Phase 1 | 98 | Zhongnan HospitalOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07446686 | Study on the Safety and Tolerability of Postoperative Radiotherapy Concurrent With CDK4/6 Inhibitors in HR+/HER2- High-Risk Breast Cancer | not yet recruiting | Early Phase 1 | 30 | Guizhou Provincial People's HospitalOTHER | 0 | Mar 3, 2026 | clinicaltrials |
| NCT03164486 | First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide | active not recruiting | Early Phase 1 | 27 | Julie L. Sutcliffe, Ph.DOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05636540 | In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma | recruiting | Early Phase 1 | 30 | Heather WachtelOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05659797 | FES BPET-DBT in Newly Diagnosed Breast Cancer | recruiting | Early Phase 1 | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06511037 | PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis | recruiting | Early Phase 1 | 10 | University of California, IrvineOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07435415 | Local Injection Methylene Blue Combined With Radiation in HNSCC Patients | active not recruiting | Early Phase 1 | 10 | China Medical University HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07429461 | Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia | recruiting | Early Phase 1 | 16 | Zhejiang UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT02356653 | Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC(ExpMACs) | recruiting | Early Phase 1 | 100 | Children's Hospital of PhiladelphiaOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03334500 | Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer | active not recruiting | Early Phase 1 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07235280 | Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma | recruiting | Early Phase 1 | 48 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07420010 | An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors. | not yet recruiting | Early Phase 1 | 24 | Weijia Fang, MDOTHER | 0 | Feb 19, 2026 | clinicaltrials |
| NCT07416240 | Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer. | recruiting | Early Phase 1 | 10 | Hainan Cancer HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03771651 | Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube | active not recruiting | Early Phase 1 | 18 | University of OklahomaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03970226 | Tocilizumab in Children With ACP | active not recruiting | Early Phase 1 | 9 | University of Colorado, DenverOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04512716 | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma | recruiting | Early Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2026source: clinicaltrials